Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
Abstract Background The oral anti‐janus kinase 1 inhibitor upadacitinib has shown a good efficacy–safety profile in the treatment of moderate‐to‐severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been published so far. Objectives To evaluate the effi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-09-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.179 |
| _version_ | 1797729125741363200 |
|---|---|
| author | Ana Batalla Hae Jin Suh‐Oh Gregorio Carretero Hernández Javier Miquel‐Miquel Rafael Botella‐Estrada Antonio Martorell‐Calatayud Virginia Sanz‐Motilva Ignasi Figueras‐Nart Angeles Flórez |
| author_facet | Ana Batalla Hae Jin Suh‐Oh Gregorio Carretero Hernández Javier Miquel‐Miquel Rafael Botella‐Estrada Antonio Martorell‐Calatayud Virginia Sanz‐Motilva Ignasi Figueras‐Nart Angeles Flórez |
| author_sort | Ana Batalla |
| collection | DOAJ |
| description | Abstract Background The oral anti‐janus kinase 1 inhibitor upadacitinib has shown a good efficacy–safety profile in the treatment of moderate‐to‐severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been published so far. Objectives To evaluate the efficacy and safety of upadactinib in clinical practice. Methods An observational and multicentric study was conducted. Inclusion criteria consisted of patients who had previously received upadacitinib in the clinical trial M19‐850 and continued treatment with upadacitinib (15 mg or 30 mg) under daily clinical practice conditions for 12 months. Demographic data, characteristics of AD, treatment response and adverse events were recorded. Preliminary results at 24‐week follow‐up are herein presented. Results A total of 26 patients (61.54% males, mean age: 35.58 years) were included in the study; of these, 92.31% received upadacitinib 30 mg at baseline. At 24 weeks, mean values of Eczema Area and Severity Index and body surface area were 2.26 and 2.37%, respectively, 82.35% of the patients reached the Investigator's Global Assessment 0/1 and the mean value of peak pruritus numerical rating scale was 1.74. Adverse events were present in 19.23% of the cases, causing one definitive treatment interruption (due to herpes zoster) and two temporary treatment discontinuations (due to temporary elevation of creatine kinase). Conclusions These data support the maintenance of the efficacy of upadacitinib at 24‐week posttrial follow‐up, with no unexpected safety concerns. More real‐world data are needed to confirm these results. |
| first_indexed | 2024-03-12T11:24:31Z |
| format | Article |
| id | doaj.art-caf7bdc22b8e476da504589f4a201ee5 |
| institution | Directory Open Access Journal |
| issn | 2768-6566 |
| language | English |
| last_indexed | 2024-03-12T11:24:31Z |
| publishDate | 2023-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | JEADV Clinical Practice |
| spelling | doaj.art-caf7bdc22b8e476da504589f4a201ee52023-09-01T12:30:54ZengWileyJEADV Clinical Practice2768-65662023-09-012357157510.1002/jvc2.179Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitisAna Batalla0Hae Jin Suh‐Oh1Gregorio Carretero Hernández2Javier Miquel‐Miquel3Rafael Botella‐Estrada4Antonio Martorell‐Calatayud5Virginia Sanz‐Motilva6Ignasi Figueras‐Nart7Angeles Flórez8Dermatology Department Complejo Hospitalario Universitario de Pontevedra, Sergas Pontevedra SpainDermatology Department Complejo Hospitalario Universitario de Pontevedra, Sergas Pontevedra SpainDermatology Department Hospital Universitario de Gran Canaria Dr. Negrín Gran Canaria SpainDermatology Department Hospital Universitario Arnau de Vilanova Valencia SpainDermatology Department Hospital Universitario y Politécnico La Fe Valencia SpainDermatology Department Hospital de Manises Valencia SpainDermatology Department Hospital de Manises Valencia SpainDermatology Department Hospital Universitario de Bellvitge Barcelona SpainDermatology Department Complejo Hospitalario Universitario de Pontevedra, Sergas Pontevedra SpainAbstract Background The oral anti‐janus kinase 1 inhibitor upadacitinib has shown a good efficacy–safety profile in the treatment of moderate‐to‐severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been published so far. Objectives To evaluate the efficacy and safety of upadactinib in clinical practice. Methods An observational and multicentric study was conducted. Inclusion criteria consisted of patients who had previously received upadacitinib in the clinical trial M19‐850 and continued treatment with upadacitinib (15 mg or 30 mg) under daily clinical practice conditions for 12 months. Demographic data, characteristics of AD, treatment response and adverse events were recorded. Preliminary results at 24‐week follow‐up are herein presented. Results A total of 26 patients (61.54% males, mean age: 35.58 years) were included in the study; of these, 92.31% received upadacitinib 30 mg at baseline. At 24 weeks, mean values of Eczema Area and Severity Index and body surface area were 2.26 and 2.37%, respectively, 82.35% of the patients reached the Investigator's Global Assessment 0/1 and the mean value of peak pruritus numerical rating scale was 1.74. Adverse events were present in 19.23% of the cases, causing one definitive treatment interruption (due to herpes zoster) and two temporary treatment discontinuations (due to temporary elevation of creatine kinase). Conclusions These data support the maintenance of the efficacy of upadacitinib at 24‐week posttrial follow‐up, with no unexpected safety concerns. More real‐world data are needed to confirm these results.https://doi.org/10.1002/jvc2.179atopic dermatitistreatmentupadacitinib |
| spellingShingle | Ana Batalla Hae Jin Suh‐Oh Gregorio Carretero Hernández Javier Miquel‐Miquel Rafael Botella‐Estrada Antonio Martorell‐Calatayud Virginia Sanz‐Motilva Ignasi Figueras‐Nart Angeles Flórez Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis JEADV Clinical Practice atopic dermatitis treatment upadacitinib |
| title | Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis |
| title_full | Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis |
| title_fullStr | Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis |
| title_full_unstemmed | Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis |
| title_short | Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis |
| title_sort | observational 24 week study to assess clinical response to upadacitinib posttrial in patients with moderate to severe atopic dermatitis |
| topic | atopic dermatitis treatment upadacitinib |
| url | https://doi.org/10.1002/jvc2.179 |
| work_keys_str_mv | AT anabatalla observational24weekstudytoassessclinicalresponsetoupadacitinibposttrialinpatientswithmoderatetosevereatopicdermatitis AT haejinsuhoh observational24weekstudytoassessclinicalresponsetoupadacitinibposttrialinpatientswithmoderatetosevereatopicdermatitis AT gregoriocarreterohernandez observational24weekstudytoassessclinicalresponsetoupadacitinibposttrialinpatientswithmoderatetosevereatopicdermatitis AT javiermiquelmiquel observational24weekstudytoassessclinicalresponsetoupadacitinibposttrialinpatientswithmoderatetosevereatopicdermatitis AT rafaelbotellaestrada observational24weekstudytoassessclinicalresponsetoupadacitinibposttrialinpatientswithmoderatetosevereatopicdermatitis AT antoniomartorellcalatayud observational24weekstudytoassessclinicalresponsetoupadacitinibposttrialinpatientswithmoderatetosevereatopicdermatitis AT virginiasanzmotilva observational24weekstudytoassessclinicalresponsetoupadacitinibposttrialinpatientswithmoderatetosevereatopicdermatitis AT ignasifiguerasnart observational24weekstudytoassessclinicalresponsetoupadacitinibposttrialinpatientswithmoderatetosevereatopicdermatitis AT angelesflorez observational24weekstudytoassessclinicalresponsetoupadacitinibposttrialinpatientswithmoderatetosevereatopicdermatitis |